ClinicalTrials.gov
public full text
Public Domain
A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors
Phase I single-institution, open-label, dose-escalating, clinical and pharmacokinetic study. The purpose is to determine the safety, tolerability and to identify the dose limiting toxicities(DLT) and recommended dose (RD) of PM02734 administered every 3 weeks, intravenously, over 30 minutes to subjects with advanced malignant solid tumors.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors#845405
- First in Human Study of M4344 in Participants With Advanced Solid Tumors#881403
- A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors#1102496
- A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors#1058296
- A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors#1010581
Record · ID 885299
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive